Advertisement

Topics

FDA Approves Pfizer’s Retacrit, the First Epoetin Alfa Biosimilar for the Treatment of Anemia

15:39 EDT 15 May 2018 | Speciality Pharma Journal

NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U.S. “As the first approved epoetin alfa …

Original Article: FDA Approves Pfizer’s Retacrit, the First Epoetin Alfa Biosimilar for the Treatment of Anemia

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Pfizer’s Retacrit, the First Epoetin Alfa Biosimilar for the Treatment of Anemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pfizer
Pfizer is a global pharmaceutical company, the largest in world based on annual sales.  In 2009, annual sales were worth $45,448m. Pfizer spend £550m on R&D in the UK alone, and have colleagues in 180 countries. Lipitor, one of its produ...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...